Beta-Adrenergic Modulation of Drug Cue Reactivity (NCT05587361) | Clinical Trial Compass
RecruitingPhase 4
Beta-Adrenergic Modulation of Drug Cue Reactivity
United States80 participantsStarted 2024-11-26
Plain-language summary
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
Who can participate
Age range21 Years β 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.